Drug Trial Radar · NCT07227350
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Sep 28, 2026
Primary completion
Feb 2031
Study completion Feb 2031
Sponsor
- Lead sponsor
- Philogen S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open label, randomized study in patients with LaBCC not eligible or refusing surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board. The primary objective of the study is to evaluate the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF, the secondary objectives of this study are to evaluate efficacy, safety and pharmacokinetics of immunocytokines. A minimum of 60 patients and a maximum of 180 evaluable patients will be randomized in a 1:1:1 ratio to one of the three different treatment arms of the study and will receive intralesional injections of: (i) Monotherapy 13 Mio IU (\~2.17 mg) L19IL2; or (ii) Monotherapy 0.4 mg L19TNF; or (iii) Combination of 13 Mio IU L19IL2 + 0.4 mg L19TNF, once weekly for 4 consecutive weeks. Patients will be followed for a maximum of 156 weeks after beginning of treatment.
Conditions
- Locally Advanced Basal Cell Carcinoma
Interventions
L19IL2Drug
Intratumoral injections
L19TNFDrug
Intratumoral injections
L19IL2/L19TNFDrug
Intratumoral injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Overall Response RateTime frame: from enrollment to week 16
Locations
18 sites in 5 countries. Site status is shown where the registry gives one.
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
Tampa, Florida · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Not yet recruiting
The Ohio State University Wexner Medical Center Clinical Laboratories
Columbus, Ohio · Not yet recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Universitaetsklinikum Augsburg
Augsburg, Germany · Recruiting
Charite Universitaetsmedizin Berlin KöR
Berlin, Germany · Recruiting
Universitaetsklinikum Essen AöR
Essen, Germany · Recruiting
Universitaetsklinikum Halle (Saale) AöR
Halle, Germany · Recruiting
Universitaetsklinikum Schleswig-Holstein AöR
Kiel, Germany · Recruiting
Universitaetsklinikum Tuebingen AöR
Tübingen, Germany · Recruiting
Andreas Syngros Hospital Of Venereal And Dermatological Diseases
Athens, Greece · Not yet recruiting
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Naples, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy · Recruiting
Humanitas Mirasole S.p.A.
Rozzano, Italy · Recruiting
Azienda Ospedaliero-Universitaria Senese
Siena, Italy · Recruiting
Hospital Clinic De Barcelona
Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.